Abstracts tagged "febuxostat and gout"

Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: 2234 • 2018 ACR/ARHP Annual Meeting
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Jung Sun Lee¹, Seokchan Hong², Jebum Won¹, Oh Chan Kwon², Ji Seon Oh², Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine,, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although febuxostat has been widely used for lowering uric acid levels because of its renal safety compared with allopurinol, data on the hepatic safety…
Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
William B. White¹ and Lhanoo Gunawardhana², ¹Cardiology, University of Connecticut School of Medicine, Farmington, CT, ²Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…
Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
MaryAnn Zhang¹, Jun Liu², Eun Ha Kang³, Rishi J. Desai⁴, Tuhina Neogi⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…
Abstract Number: 7L • 2016 ACR/ARHP Annual Meeting
Overall Reduction in Acute Flares during Treatment with Febuxostat Compared with Placebo over 2 Years in Patients with Early Gout
Nicola Dalbeth¹, Kenneth G. Saag², William Palmer³, Hyon K. Choi³, Barbara Hunt⁴, Patricia MacDonald⁴, Ulrich Thienel⁵ and Lhanoo Gunawardhana⁴, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Birmingham, AL, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Takeda Pharmaceuticals International, Deerfield, IL, ⁵RRD International, Rockville, MD

Background/Purpose: No clinical trials have previously investigated the frequency of acute flares in early gout or the benefit of instituting urate-lowering therapy (ULT) earlier in…
Abstract Number: 198 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment
Lhanoo Gunawardhana¹, Michael A. Becker², Andrew Whelton³, Barbara Hunt¹, Majin Castillo¹, Xinxin Dong¹ and Kenneth Saag⁴, ¹Takeda Pharmaceuticals International, Deerfield, IL, ²Medicine, University of Chicago, Chicago, IL, ³Johns Hopkins University, Hunt Valley, MD, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…
Abstract Number: 199 • 2016 ACR/ARHP Annual Meeting
A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout
Kenneth Saag¹, Michael A. Becker², Andrew Whelton³, Barbara Hunt⁴, Majin Castillo⁴, Krisztina Kisfalvi⁴ and Lhanoo Gunawardhana⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Chicago, Chicago, IL, ³Johns Hopkins University, Hunt Valley, MD, ⁴Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: Data generated by Phase 1 and 2 studies suggest that the extended-release (XR) formulation of febuxostat (FBX) may provide equal or better reduction in…
Abstract Number: 210 • 2016 ACR/ARHP Annual Meeting
Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Neus Quilis¹, Mariano Andrés^1,2, Carlos Muñoz³, Paloma Vela^1,2 and Eliseo Pascual⁴, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Sección de Inmunología, Hospital General Universitario de Alicante, Alicante, Spain, ⁴Departamento de Medicina Clínica, Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Allopurinol is the most used urate-lowering agent for patients with gout, but around 10% of patients show intolerance to this drug, often at skin,…
Abstract Number: 97 • 2015 ACR/ARHP Annual Meeting
Genomic Sequencing of Uric Acid Metabolizing and Clearing Genes in Relationship to Xanthine Oxidase Inhibitor Dose
Matthew Carroll¹, Kristen Cook² and Thomas Shaak³, ¹Rheumatology, Keesler Medical Center, Keesler AFB, MS, ²Internal Medicine, Keesler Medical Center, Keesler AFB, MS, ³Clinical Research Laboratory, Keesler Medical Center, USAF, Keesler AFB, MS
Background/Purpose: Effective long term uric acid lowering therapy with the xanthine oxidase inhibitors (XOI) allopurinol and febuxostat exists. When compliant with therapy, it is unclear…
Abstract Number: 2350 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study
Pierre-Antoine Juge¹, Marie-Elise Truchetet², Sébastien Ottaviani³, Cécile Vigneau⁴, Clotilde Loustau⁵, Divi Cornec⁶, Tristan Pascart⁷, Emilie Cornec-Legall⁸, Marine Florien⁹, Florian Bailly¹⁰, Thierry Schaeverbeke⁵, Alain Saraux¹¹, Philippe Dieude¹², Rene-Marc Flipo¹³, Georges Jean-Baptiste¹⁴, Pascal Richette¹⁵, Frederic Lioté¹⁶, Thomas Bardin^17,18, Gerard H. Chales¹⁹ and Hang-Korng Ea²⁰, ¹Rheumatology Department, Centre de Viggo Petersen, Lariboisère Hospital, Paris, France, ²Rheumatology, Pellegrin Hospital, Bordeaux, France, ³Hopital Lariboisière, Paris, France, ⁴Nephrology, Rennes University Hospital, Rennes, France, ⁵Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ⁶Department of rheumatology, Brest Occidentale University, Brest, France, ⁷Rheumatology, Saint-Philibert Hospital, Lille, France, ⁸Nephrology Departement, Brest Hospital, Brest, France, ⁹Rheumatology Department, Pierre-Zobda-Quitman La Meynard, Fort-de-France, France, ¹⁰Rheumatology Department, La Pitié-Salpétrière Hospital, Paris, France, ¹¹Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹²Rheumatology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ¹³Rheumatology, University Hospital, Lille, France, ¹⁴Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort-de-France, Martinique, ¹⁵Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, ¹⁶Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹⁷Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁸Rhumatology Departement, Hôpital Lariboisière, Paris, France, ¹⁹CHU RENNES, Rennes, France, ²⁰INSERM UMR1132, Paris Diderot University, Paris, France
Background/Purpose: Although allopurinol is the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD…
Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].